Response of Doxorubicin-induced Cardiomyopathy to the Current Management Strategy of Heart Failure
- 31 December 2005
- journal article
- Published by Elsevier BV in The Journal of Heart and Lung Transplantation
- Vol. 24 (12), 2196-2201
- https://doi.org/10.1016/j.healun.2004.12.108
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Long-Term Enalapril Therapy for Left Ventricular Dysfunction in Doxorubicin-Treated Survivors of Childhood CancerJournal of Clinical Oncology, 2002
- β-Blockade in adriamycin-induced cardiomyopathyJournal of Cardiac Failure, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Doxorubicin-Induced CardiomyopathyNew England Journal of Medicine, 1998
- Doxorubicin‐induced cardiomyopathy treated with carvedilolClinical Cardiology, 1998
- The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart FailureNew England Journal of Medicine, 1996
- Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patientsAmerican Heart Journal, 1995
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Heart Transplantation in a Child with Doxorubicin-Induced CardiomyopathyNew England Journal of Medicine, 1988
- Reversible doxorubicin-induced congestive heart failureArchives of Internal Medicine, 1982